share_log

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Ocugen將於美國東部時間5月14日星期二上午8點30分舉行電話會議,討論業務更新和2024年第一季度財務業績
Ocugen ·  05/03 12:00

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024.

賓夕法尼亞州馬爾文,2024年5月3日(GLOBE NEWSWIRE)——專注於發現、開發和商業化新型基因和細胞療法及疫苗的生物技術公司Ocugen公司(Ocugen或公司)(納斯達克股票代碼:OCGN)今天宣佈,它將舉辦電話會議和網絡直播,討論公司2024年第一季度的財務業績,並於美國東部時間週二上午8點30分提供業務最新情況,2024 年 5 月 14 日。

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Ocugen將在同一天發佈盤前收益公告。邀請與會者使用以下詳細信息參加電話會議:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 8699924
Webcast: Available on the events section of the Ocugen investor site

撥入號碼:(800) 美國來電者爲 715-9871,國際來電者爲 (646) 307-1963
會議 ID:8699924
網絡直播:可在 事件 Ocugen 的部分 投資者網站

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

電話會議和存檔網絡直播的重播將在活動結束後的大約45天內在Ocugen上播出 投資者網站

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

關於 Ocugen, Inc.
Ocugen, Inc. 是一家生物技術公司,專注於發現、開發和商業化能夠改善健康併爲全球患者帶來希望的新型基因和細胞療法和疫苗。我們正在通過勇敢的創新對患者的生活產生影響——開闢新的科學道路,利用我們獨特的智力和人力資本。我們的突破性修飾基因療法平台有可能用單一產品治療多種視網膜疾病,我們正在推進傳染病研究,以支持公共衛生和骨科疾病,以滿足未得到滿足的醫療需求。在以下網址了解更多 www.ocugen.com 然後關注我們 X領英

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

關於前瞻性陳述的警示說明
本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述,這些陳述存在風險和不確定性。在某些情況下,我們可能會使用 “預測”、“相信”、“潛力”、“提議”、“繼續”、“估計”、“預期”、“期望”、“計劃”、“打算”、“可能”、“可能”、“可能”、“可能”、“將”、“應該” 或其他傳達未來事件或結果不確定性的詞語來識別這些前瞻性陳述。此類陳述受許多重要因素、風險和不確定性的影響,這些因素可能導致實際事件或結果與我們當前的預期存在重大差異。我們在向美國證券交易委員會(SEC)提交的定期文件中更全面地描述了這些以及其他風險和不確定性,包括我們在向美國證券交易委員會提交的季度和年度報告中標題爲 “風險因素” 的部分中描述的風險因素。我們在本新聞稿中作出的任何前瞻性陳述僅代表截至本新聞稿發佈之日。除非法律要求,否則在本新聞稿發佈之日之後,我們沒有義務更新本新聞稿中包含的前瞻性陳述,無論是由於新信息、未來事件還是其他原因。

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

聯繫人:
蒂芙尼漢密爾頓
傳播主管
Tiffany.Hamilton@ocugen.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論